Texas Prostate Completes 100th MRI-Guided TULSA Procedure in Dallas
Texas Prostate, led by Dr. James Cochran, has completed its 100th TULSA Procedure at Dallas Medical Center. The milestone marks a significant expansion in the use of this MRI-guided therapy for prostate conditions. Profound Medical Corp., the developer behind the technology, has recognised the team's achievement as adoption of the procedure grows. The TULSA Procedure uses robotically controlled ultrasound to heat and destroy diseased prostate tissue while sparing surrounding nerves. Real-time MRI thermography allows doctors to monitor and adjust temperatures automatically, ensuring precision and safety. This method contrasts with older treatments like HIFU, which Dr. Cochran noted had a narrower range of applications and higher risks.
The shift to a Medicare-supported model at Dallas Medical Center helped Texas Prostate increase its TULSA Procedure numbers by 500%. The collaboration made the treatment more accessible to patients, accelerating its use. By the end of 2025, Profound Medical reported 78 TULSA-PRO systems installed globally, with major US sites including Texas Prostate and Mount Sinai Hospital in New York. The company projects around 120 installations by the end of 2026.
The procedure treats both prostate cancer and benign prostatic hyperplasia (BPH). Its ability to provide continuous MRI visualization during treatment reduces complications and improves outcomes. Profound Medical, a commercial-stage medical device company, specialises in AI-powered, incision-free therapies for tissue ablation. The 100th TULSA Procedure at Texas Prostate reflects the growing adoption of this advanced treatment. With more clinics installing the TULSA-PRO system, access to the therapy is expanding. The technology's precision and safety continue to attract doctors and patients seeking alternatives to traditional prostate treatments.
